Average Insider

Where insiders trade, we follow

$CLYM
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Healthcare
Sector
Biotechnology
Industry
Aoife Brennan BCh MMSc
CEO
17
Employees
$10.77
Current Price
$382.51M
Market Cap
52W Low$1.16
Current$10.7784.9% above low, 15.1% below high
52W High$12.48

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys00---
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
No transactions in the last 3 months. Sign up free to see 12 months of history.

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Mar 24, 2026
EPS
Estimated-$0.19
ActualN/A
Revenue
EstimatedN/A
ActualN/A
2 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.5.2